Immunomodulatory effect of macrolides: At what cost?
We present the case of a 60-year old female patient, with a 10 year history of non-CF bronchiectasis and use of macrolides as maintenance immunomodulatory treatment, who was diagnosed with macrolide-resistant Mycobacterium avium complex lung disease. Macrolides' immunomodulatory effect is appea...
Main Authors: | Maria Kipourou, Katerina Manika, Apostolos Papavasileiou, Georgia Pitsiou, Martha Lada, Evangelos Ntinapogias, Ioannis Kioumis |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007116300041 |
Similar Items
-
Bronchiectasis: an emerging global epidemic
by: Sanjay H. Chotirmall, et al.
Published: (2018-05-01) -
Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore
by: Albert Y. H. Lim, et al.
Published: (2018-05-01) -
Chronic infection with non-tuberculous mycobacteria in patients with non-CF bronchiectasis: Comparison with other pathogens
by: Giulia Bonaiti, et al.
Published: (2015-01-01) -
Expert recommendations on the role of macrolides in chronic respiratory diseases
by: Raja Dhar, et al.
Published: (2021-01-01) -
Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis
by: Paola Faverio, et al.
Published: (2016-11-01)